The estimated Net Worth of Paul S Echenberg is at least $1.15 Миллион dollars as of 23 April 2012. Paul Echenberg owns over 2,091 units of Angiodynamic Inc stock worth over $1,145,737 and over the last 20 years Paul sold ANGO stock worth over $0.
Paul has made over 2 trades of the Angiodynamic Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Paul exercised 2,091 units of ANGO stock worth $13,633 on 23 April 2012.
The largest trade Paul's ever made was exercising 2,091 units of Angiodynamic Inc stock on 23 April 2012 worth over $13,633. On average, Paul trades about 190 units every 15 days since 2004. As of 23 April 2012 Paul still owns at least 154,412 units of Angiodynamic Inc stock.
You can see the complete history of Paul Echenberg stock trades at the bottom of the page.
Paul's mailing address filed with the SEC is 623 SYDENHAM AVE, , WESTMONT QUEBEC CANADA, A8, H3Y 2Z3.
Over the last 20 years, insiders at Angiodynamic Inc have traded over $207,843,757 worth of Angiodynamic Inc stock and bought 255,612 units worth $3,086,102 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman и Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of $826,492. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth $32,937.
founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie
Angiodynamic Inc executives and other stock owners filed with the SEC include: